CYBERMED NEWS - Higher Medical Scientifc Information and Research

BIOTECHNOLOGY

COVID 19: Halix ready for vaccine production

Dutch Halix BV will manufacture a ChAdOx1 nCoV-19 vaccine, developed at the University of Oxford . Dutch CDMO HALIX B.V. has joined a research consortium coordinated by the University of Oxford,...

Mobidiag’s COVID-19 test okayed for emergency use

Molecular diagnostics specialist Mobidiag Ltd has got emergency approval for its Amplidiag® COVID-19 molecular diagnostic test in Finland.

COVID-19: Solnatide approved for compassionate use

Austrian COVID-19 patients with severe lung dysfunction for the first time have a treatment option within a compassionate use program for Apeptico's solnatide. The more COVID-19 patients reach advanced disease...

Apeptico gets EU grant for COVID-19 drug

Austrian APEPTICO has got Horizon 2020 money for accelerated development and clinical use of Solnatide for the treatment of COVID-19 patients According to the Viennese company, 20% of hospitalised...

Novacyt inks contract on Covid-19 diagnostics

Paris-based Novacyt SA has signed a global distribution agreement with Bruker Ltd for its COVID-19 diagnostic test. Novacyt SA ’s British molecular diagnostics division Primerdesign Ltd (Camberley) signed a...

BioNTech SE’s COVID-19 vaccine attracts investment

Chinese Fosun Pharma Ltd has made the largest investment in a foreign company for a COVID-19 vaccine development: BioNTech’d mRNA vaccine BNT162. Under the deal, Chinese Fosun Pharmaceutical (Group)...

Wuxi Biologics and Vir Biotechnology announce mAbs development collaboration to...

Chinese CDMO WuXi Biologics has linked up with San Francisco biotech firm Vir Biotechnology to develop and manufacture human monoclonal antibodies (mAbs) to potentially treat coronavirus disease (COVID-19), the two...

MercachemSyncom, Bionetix, and ProQinase ink AML contract

Bionetix, ProQinase, and MercachemSyncom have announced that they will jointly develop a new AML drug, from target identification to clinical testing

iOnctura SA bags €15m in Series A round

Merck KGaA’s 2017 Swiss cancer spin-out iOnctura SA has raised €15m to bring its PI3Kδ inhibitor and autotaxin inhibitor to the clinic.
Prev123Next
Biotechnology : nature.com


We use cookies on our website. Some of them are essential for the operation of the site, while others help us to improve this site and the user experience (tracking cookies). You can decide for yourself whether you want to allow cookies or not. Please note that if you reject them, you may not be able to use all the functionalities of the site.